Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuyang Yunshu traditional Chinese medicine granules is a proprietary herbal formulation developed by the Guangdong Provincial Hospital of Traditional Chinese Medicine. The drug is based on the Traditional Chinese Medicine (TCM) therapeutic principle of "Fuyang Yunshu," which focuses on supporting Yang energy and regulating the body's metabolic "pivot" (typically associated with the Spleen and Stomach systems). It is currently being evaluated in clinical trials for the treatment of metabolic syndrome and preclinical atherosclerosis. The granules are intended to improve metabolic risk markers and reduce carotid intima-media thickness (CIMT) in adult patients. As a TCM formulation, it likely exerts its effects through multi-component and multi-target pathways, including the modulation of lipid metabolism and the reduction of systemic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuyang Yunshu traditional Chinese medicine granules.